

Association for the Chronically Mentally III (ACMI)

December 9th, 2020

The webinar will start @ 5:30PM

ACMI Educational Webinar:

The Impact of Substance Use on the Developing Adolescent Brain by Dr.
Shawn Kelly

- Information presented is not medical advice
- Please mute all lines except presenters
- Submit questions in chat window
- Those requesting a Certificate of Attendance need to send an email to <u>contact@acmionline.com</u> with following information:
 - First name
 - Last name
 - Email address
- Meghan Skrobel | Copa Education will be sending the certificate

ACMI BOARD OF

DIRECTORS

- Josh Mozell, Esq.- President
- Laurie Goldstein Vice President
- Charles Goldstein, M.D. Treasurer
- Dick Dunseath Secretary
- Holly Gieszl, Esq. Board
- Deborah Geesling Board
- Barbara Honiberg Board
- Len Tamsky, M.D. Board

INTRODUCTIONS



TODAY'S SPEAKER

 Dr. Shawn Kelly is a Pediatric Addition Medicine Fellow at Boston Children's Hospital

ACMI Educational Webinar:


A conversation with Dr Kenneth Paul Rosenberg- author of Bedlam: An Intimate Journey Into America's Mental Health Crisis

- Information presented is not medical advice
- Please mute all lines except presenters
- Submit questions in chat window
- Those requesting a Certificate of Attendance need to send an email to <u>contact@acmionline.com</u> with following information:
 - First name
 - Last name
 - Email address
- Diana Medina, Ph.D. | Copa Chief of Clinical Education will be sending the certificate



© Boston Children's Hospital 2019. All Rights Reserved. For permissions contact ASAP project manager at asap@childrens.harvard.edu

Brain weight by age



Source: Dekaban, A.S. and Sadowsky, D. (1978). Annals of Neurology, 4:345-356.

Neuron growth in brain development







Image retrieved from: http://etec.ctlt.ubc.ca/510wiki/Brain-based Learning


Brain maturation









































Activation of the reward pathway by addictive drugs






Adolescents are developmentally primed to use drugs



Most drug use starts in adolescence



Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.


Adolescents are developmentally vulnerable to develop substance use disorders








Anandamide












Receptor binding in brain tissue

Compound	Potency relative to THC
(-)-Delta9-THC	1
Anandamide	.47*

^{*}The affinity of anandamide for cannabinoid receptors ranges from about one-fourth to one-half that of THC. The differences depend on the cells or tissue that are tested and on the experimental conditions, such as the binding assay used.

THC vs. Anandamide



Source: Joy J, Watson SJ, Benson JJ, eds. (1999). Cannabinoids and animal physiology. In: *Marijuana and Medicine: Assessing the Science Base*. Washington, DC: Division of Neuroscience and Behavioral Health -Institute of Medicine. National Academies Press.

Long-term effects associated with marijuana use in adolescence

Psychosis¹

Depression^{2,3,4}

Anxiety⁴


Diminished life satisfaction and achievement^{5,6,7}

Cognitive decline8,9

Addiction^{10,11}

^{1.} Griffith-Lendering, et al. (2013). 2. Manrique-Garcia, et al. (2012). 3. Fairman BJ & Anthony JC (2012). 4. Patton GC, et al. (2002). 5. Fergusson DM, Horwood LJ, & Swain-Campbell N (2000). 6. Fergusson DM & Boden JM (2008). 7. Brook JS, et al. (2013). 8. Meier MH, et al. (2012). 9. Zalesky A, et al. (2012). 10. Lopez-Quintero C, et al. (2011). 11. Hall W & Degenhardt L (2009).

Memory impairment





Persistent cannabis users show neuropsychological decline from childhood to midlife

Madeline H. Meier^{a,b,1}, Avshalom Caspi^{a,b,c,d,e}, Antony Ambler^{e,f}, HonaLee Harrington^{b,c,d}, Renate Houts^{b,c,d}, Richard S. E. Keefe^d, Kay McDonald^f, Aimee Ward^f, Richie Poulton^f, and Terrie E. Moffitt^{a,b,c,d,e}

^aDuke Transdisciplinary Prevention Research Center, Center for Child and Family Policy, ^bDepartment of Psychology and Neuroscience, and ^cInstitute for Genome Sciences and Policy, Duke University, Durham, NC 27708; ^dDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710; ^eSocial, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London SE5 8AF, United Kingdom; and ^fDunedin Multidisciplinary Health and Development Research Unit, Department of Preventive and Social Medicine, School of Medicine, University of Otago, Dunedin 9054, New Zealand

The Dunedin Study

N = 1,037



13 yrs 18 yrs 21 yrs (Pre-initiation)

1 2 3 4 5

Assessment ages

32 yrs

38 yrs

The Dunedin Study

N = 1,037



13 yrs



18 yrs



21 yrs 32 yrs




38 yrs

(Pre-initiation)


1 2 3 4 5

Assessment ages



Healthy non-user

Daily MJ user



Source: Arnone D, Barrick TR, Chengappa S et al. (2008). Corpus callosum damage in heavy marijuana use: Preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. *Neuro Image* 41:1067-1074.


Marijuana



- Hallucinations (27%)
- Paranoia/Anxiety (33.6%)
- Any psychotic symptom (42.9%)

Levy S, Weitzman, ER. Acute mental health symptoms in adolescent marijuana users. *JAMA Pediatrics*. 2018 Dec 17;doi 10.1001/jamapediatrics.2018

Marijuana use and psychotic disorders



A meta-analysis of 6 studies found an increased risk of psychotic outcome among those who used cannabis most frequently compared with non-users (Adjusted Odds Ratio: 2.09, 95% CI: 1.54-2.84).

Association between cannabis use and schizoaffective disorder

	# Exposure	# Cases	HR Crude	HR adjusted*
Never used cannabis	39, 978	47	1	1
Ever used cannabis	5,109	12	2.1 (1.1-3.8)	0.8 (0.2-2.9)
>50 times	855	7	7.5 (3.4-16.7)	7.4 (1.0-54.3)

^{*}Adjustments for: prior personality disorders at conscription, IQ, disturbed behavior in childhood, social adjustment, risky use of alcohol, smoking, early adulthood socioeconomic position, use of other drugs, brought up in a city. The category "Ever used cannabis" includes all individuals who reported cannabis use, including those who reported ">50 times".

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review



Theresa HM Moore, Stanley Zammit, Anne Lingford-Hughes, Thomas RE Barnes, Peter B Jones, Margaret Burke, Glyn Lewis

Summary

Background Whether cannabis can cause psychotic or affective symptoms that persist beyond transient intoxication is unclear. We systematically reviewed the evidence pertaining to cannabis use and occurrence of psychotic or affective mental health outcomes.

Methods We searched Medline, Embase, CINAHL, PsycINFO, ISI Web of Knowledge, ISI Proceedings, ZETOC, BIOSIS, LILACS, and MEDCARIB from their inception to September, 2006, searched reference lists of studies selected for inclusion, and contacted experts. Studies were included if longitudinal and population based, 35 studies from 4804 references were included. Data extraction and quality assessment were done independently and in duplicate.

The evidence is consistent with the view that cannabis increases risk of psychotic outcomes independently of confounding and transient intoxication effects.

strong. The uncertainty about whether cannabis causes psychosis is unlikely to be resolved by further longitudinal studies such as those reviewed here. However, we conclude that there is now sufficient evidence to warn young people that using cannabis could increase their risk of developing a psychotic illness later in life.

Lancet 2007: 370-319-28


See Editorial page 292

See Comment page 293


Academic Unit of Psychiatry ITH M Moore MSc. S Zammit Phill. A Unigford-Hughes PhD, G Lewis PhD) and Department. of Social Medicine

(M. Burke M.Sc), University of Bristol, Bristol, UK; Department of Psychological Medicine, Cardiff University, Cardiff, UK (SZammit); Department of Psychological Medicine, Imperial College, London, UK (TREBarnes DSc); and Department of Psychiatry, Cambridge University, Cambridge, UK (P.H.)ones PhD)

Correspondence to: Dr Stanley Zammit, Department of Psychological Medicine, Cardiff University, Cardiff CFL4 AXNUUK rammittedscarde at uk




ILLICIT DRUG USE




PAST YEAR ILLICIT DRUG USE


Past year use among 12th graders



DAILY MARIJUANA USE IN LOWER GRADES INCREASES BUT PAST YEAR MARIJUANA USE STEADY




PRESCRIPTION DRUG MISUSE CONTINUES DECLINE FROM PEAK YEARS




Vaping & Cannabis Trends Among Young Adults (19-22) | National Institute on Drug Abuse (NIDA)

ADDERALL® MISUSE SEES SIGNIFICANT CHANGES IN PAST 5 YEARS


a decrease in 10th and 12th grades, but an increase in 8th grade



TOBACCO AND NICOTINE: VAPING THREATENS PROGRESS




ALCOHOL USE CONTINUES ITS DECLINE




VAPING & CANNABIS TRENDS AMONG YOUNG ADULTS (19-22)

2019 Monitoring the Future College Students and Young Adults Survey Results


Past month **NICOTINE VAPING** rose dramatically over 3 years.



Past month **CANNABIS VAPING** increased sharply among non-college young adults in 2019.



Past year **CANNABIS USE** remained at historic highs.




Vaping & Cannabis Trends Among Young Adults (19-22) | National Institute on Drug Abuse (NIDA)

Daily **CANNABIS USE** was more common among non-college young adults in 2019.

Daily use* of cannabis was nearly 3x as high among young adults not attending college compared to peers in college.

DAILY USE 2019





*Cannabis use on 20 or more occasions in past 30 days

Figures have been rounded to the nearest whole number.



